 Today I have the pleasure of speaking with Thomas Spink, president, CEO and co-founder of Hemastemix. Hello, Thomas. How are you doing? Good afternoon, Stephen. Very well. Thanks. How are you? I'm doing well. Thanks. And you must be a very happy man today. You reported some very good news this morning, and while other companies are suffering in the markets, your stock at one point was up almost 15%. So let's talk about your news. Sure. Well, we announced today the final step in the litigation settlement agreement. We settled with our opponents, and this gives us back the intellectual property that is Hemastemix that was controlled by our opponents, including the clinical trial data, the randomization tables, which enable us to analyze the phase two clinical trial data. And all of our historical information that was originally at Hemastemix Israel, including the randomization table that governs the subjects that were treated in this clinical trial in South Africa. So it's actually a very, very significant day for Hemastemix and its shareholders. Yeah. And you probably don't know this about me. I'm a recovering lawyer. So when someone wins a lawsuit, I consider that a very big deal, and especially you are a medical technology company, and your intellectual property is everything. You can come up with the best process in the world, but if you don't own it, then you own nothing. So today's news release says that all of your intellectual property has been returned to Hemastemix, and now you have a way forward. Yes, exactly right. And to your point, this is a very significant intellectual property portfolio. It is governed by some 91 patents. What we do, Steven, is we take a cup of blood from the patient's arm, derive their stem cells from it in the space of five days, culture the patient's own stem cells in their blood serum, and we create three different stem cell lines, an angiogenic cell precursor that has been used to treat some 500 subjects, a neuronal cell precursor, and a heart cell precursor. The results that we have published are significant. We've demonstrated in a randomized clinical trial 20 patients where 10 received ACP and 10 received a placebo. After two years of follow-up, there were two deaths, and six of eight limbs lost to amputation in the placebo arm. There were no deaths, and seven of 10 limbs saved from amputation in the treated arm. And that parallels many of our published results in ischemic heart disease as well as COPD. Those are remarkable results, especially if someone's in danger of losing an arm or if they got cardiomyopathy or any of the sorts of things where the lack of blood flow is important to those people. That is wonderful news going forward. And again, today's news is that you own all of that now, and you can continue to develop without your shareholders worrying that someone else is going to steal your technology. Indeed, yes. And so we have quite a task ahead of us. It's not for the faint of heart, but I think when you compare our valuation with our peers, I think it's still a very good entry point for anyone who has appetite for biotech risk capital. Now that you've got the intellectual property issues cleared out of the way, what's next for you, Ms. Nevers? So we will complete the analysis of the Phase 2 clinical trial and I predict announce a Phase 3 clinical trial as we have sufficient evidence in the preliminary data and in the other published data that the product is safe. And as you know, that's really the point of a Phase 2 clinical trial. Phase 3, you really want to demonstrate that it's not only safe, but also efficacious. We believe that, again, that the historical clinical data we have published is very indicative of the future for human stemming. And where were the clinical trials taking place? This was as the current Phase 2 clinical trial was in 17 teaching hospitals across North America, some well, regarded institutions such as U of T, UBC here in Canada, Florida, Shands as another example. No, well, and now you've cleared the path moving forward and I suspect you're going to be a very popular man in terms of the markets as well, especially in these days when everyone is struggling a little bit, you definitely are standing out today. Yes, yes. No, today is a standout day and we're delighted. Well, it's great. Well, thank you, Thomas. I look forward to chatting again soon and hear how your clinical trials are going. And please come back and update us. I'm sure that our viewers want to follow what's going on now that you've cleared the decks for action. Thank you very much, Stephen. Pleasure to speak with you.